These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12969967)

  • 1. Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs.
    Zhang J; Xu L; Haskins ME; Parker Ponder K
    Blood; 2004 Jan; 103(1):143-51. PubMed ID: 12969967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
    Cohn EF; Zhuo J; Kelly ME; Chao HJ
    J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
    Xu L; Mei M; Haskins ME; Nichols TC; O'donnell P; Cullen K; Dillow A; Bellinger D; Ponder KP
    Thromb Res; 2007; 120(2):269-80. PubMed ID: 17095052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
    Xu L; Gao C; Sands MS; Cai SR; Nichols TC; Bellinger DA; Raymer RA; McCorquodale S; Ponder KP
    Blood; 2003 May; 101(10):3924-32. PubMed ID: 12531787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
    Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL
    Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
    Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
    J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
    Levin D; Lagassé HA; Burch E; Strome S; Tan S; Jiang H; Sauna ZE; Golding B
    J Thromb Haemost; 2017 Apr; 15(4):721-734. PubMed ID: 28166609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4.
    Sack BK; Wang X; Sherman A; Rogers GL; Markusic DM
    Haemophilia; 2015 Jan; 21(1):133-9. PubMed ID: 25417755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
    Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
    Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.
    Miao CH; Thompson AR; Loeb K; Ye X
    Mol Ther; 2001 Jun; 3(6):947-57. PubMed ID: 11407909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral vector-modified bone marrow stromal cells secrete biologically active factor IX in vitro and transiently deliver therapeutic levels of human factor IX to the plasma of dogs after reinfusion.
    Cherington V; Chiang GG; McGrath CA; Gaffney A; Galanopoulos T; Merrill W; Bizinkauskas CB; Hansen M; Sobolewski J; Levine PH; Greenberger JS; Hurwitz DR
    Hum Gene Ther; 1998 Jul; 9(10):1397-407. PubMed ID: 9681411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep.
    David AL; McIntosh J; Peebles DM; Cook T; Waddington S; Weisz B; Wigley V; Abi-Nader K; Boyd M; Davidoff AM; Nathwani AC
    Hum Gene Ther; 2011 Apr; 22(4):419-26. PubMed ID: 20919876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In utero gene transfer of human factor IX to fetal mice can induce postnatal tolerance of the exogenous clotting factor.
    Waddington SN; Buckley SM; Nivsarkar M; Jezzard S; Schneider H; Dahse T; Kemball-Cook G; Miah M; Tucker N; Dallman MJ; Themis M; Coutelle C
    Blood; 2003 Feb; 101(4):1359-66. PubMed ID: 12393743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for contribution of CD4+ CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery.
    Nivsarkar MS; Buckley SM; Parker AL; Perocheau D; McKay TR; Rahim AA; Howe SJ; Waddington SN
    J Immunol Res; 2015; 2015():397879. PubMed ID: 25759840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.
    Ge Y; Powell S; Van Roey M; McArthur JG
    Blood; 2001 Jun; 97(12):3733-7. PubMed ID: 11389010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
    Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
    Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells.
    Wang JM; Zheng H; Sugahara Y; Tan J; Yao SN; Olson E; Kurachi K
    Hum Gene Ther; 1996 Sep; 7(14):1743-56. PubMed ID: 8886845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.
    Ye X; Loeb KR; Stafford DW; Thompson AR; Miao CH
    J Thromb Haemost; 2003 Jan; 1(1):103-11. PubMed ID: 12871546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Exploration of high expressions of retroviral vectors containing hFIX minigene in murine myoblast cells].
    Hou J; Wang J; Min B
    Zhonghua Xue Ye Xue Za Zhi; 2001 Mar; 22(3):121-4. PubMed ID: 11877060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.